Institution Directory

Clinical trials at Beth Israel Deaconess Medical Center

Sites in Boston, MA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

619

Shown on this page

Current sort

Live official records

Conditions: Coronary Artery Calcification, Coronary Artery Disease, Stenotic Coronary Lesion
Interventions: Experimental; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 40
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 33 more

Conditions: Ventricular Tachycardia (VT)
Interventions: Sphere-9 Catheter with the Affera Mapping and Ablation System; Device
Lead sponsor: Medtronic Cardiac Ablation Solutions; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Boston, Massachusetts • New York, New York • Cleveland, Ohio + 3 more

Conditions: Cytomegalovirus (CMV), HIV (Human Immunodeficiency Virus)
Interventions: VIR-1388, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Birmingham, Alabama • Boston, Massachusetts

Conditions: Newly Diagnosed Multiple Myeloma
Interventions: Isatuximab, Iberdomide, Bortezomib, Dexamethesone; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Liver Transplantation, Biomarkers
Interventions: LiverCare; Device
Lead sponsor: CareDx; Industry
Eligibility: 12 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 26
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 22 more

Conditions: Prostatic Neoplasms
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 21 Years and older · Male only
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2032
U.S. locations: 10
States / cities: San Francisco, California • Stanford, California • Atlanta, Georgia + 5 more

Conditions: Breast Cancer
Interventions: Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression; Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 3,960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2034
U.S. locations: 1226
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 809 more

Conditions: Hidradenitis Suppurativa
Interventions: Lutikizumab, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years and older
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 73
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 64 more

Conditions: Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Synchronous Bilateral Breast Carcinoma
Interventions: Health Education Program, Weight Loss Intervention; Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3,177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2030
U.S. locations: 1464
States / cities: Daphne, Alabama • Mobile, Alabama • Anchorage, Alaska + 921 more

Conditions: Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Interventions: Patritumab Deruxtecan (Fixed dose), Patritumab Deruxtecan (Up-Titration); Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 33
States / cities: Gilbert, Arizona • Duarte, California • La Jolla, California + 27 more

Conditions: Waldenstrom Macroglobulinemia
Interventions: Zanubrutinib, Bendamustine, Rituximab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 5
States / cities: Denver, Colorado • Boston, Massachusetts • Dallas, Texas

Conditions: Primary Biliary Cirrhosis
Interventions: Elafibranor 80mg, Placebo; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 46
States / cities: Chandler, Arizona • Los Angeles, California • Sacramento, California + 34 more

About this Beth Israel Deaconess Medical Center institution page

What this page lists: ClinicalTrials.gov records that list Beth Israel Deaconess Medical Center in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Beth Israel Deaconess Medical Center

Filter and sort this campus

Live official records

TECTONIC CAD IVL IDE Study

Safety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere-9 VT EFS)

A Clinical Study to Evaluate the Safety and Immunogenicity of a Higher Dose of the Study Vaccine, VIR-1388, in HCMV-seropositive Adult Participants Without HIV

Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma

Molecular Assessment and Profiling of Liver Transplant Recipients

Prostate Active Surveillance Study

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

Breast Cancer WEight Loss Study (BWEL Study)

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM

Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)

About this Beth Israel Deaconess Medical Center institution page